These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31908953)

  • 21. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector.
    Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C
    Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
    Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
    Mader KM; Beard H; King BM; Hopwood JJ
    Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain Targeting in MPS-IIIA.
    Sorrentino NC; Fraldi A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():630-8. PubMed ID: 27491210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin.
    Xenocostas A; Cheung WK; Farrell F; Zakszewski C; Kelley M; Lutynski A; Crump M; Lipton JH; Kiss TL; Lau CY; Messner HA
    Eur J Clin Pharmacol; 2005 May; 61(3):189-95. PubMed ID: 15776276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA.
    Sorrentino NC; Cacace V; De Risi M; Maffia V; Strollo S; Tedesco N; Nusco E; Romagnoli N; Ventrella D; Huang Y; Liu N; Kalled SL; Choi VW; De Leonibus E; Fraldi A
    Mol Ther Methods Clin Dev; 2019 Dec; 15():333-342. PubMed ID: 31788497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continual Low-Dose Infusion of Sulfamidase Is Superior to Intermittent High-Dose Delivery in Ameliorating Neuropathology in the MPS IIIA Mouse Brain.
    Beard H; Hassiotis S; Luck AJ; Rozaklis T; Hopwood JJ; Hemsley KM
    JIMD Rep; 2016; 29():59-68. PubMed ID: 26620043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement reduces neuropathology in MPS IIIA dogs.
    Crawley AC; Marshall N; Beard H; Hassiotis S; Walsh V; King B; Hucker N; Fuller M; Jolly RD; Hopwood JJ; Hemsley KM
    Neurobiol Dis; 2011 Aug; 43(2):422-34. PubMed ID: 21550404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Residual activity and proteasomal degradation of p.Ser298Pro sulfamidase identified in patients with a mild clinical phenotype of Sanfilippo A syndrome.
    Muschol N; Pohl S; Meyer A; Gal A; Ullrich K; Braulke T
    Am J Med Genet A; 2011 Jul; 155A(7):1634-9. PubMed ID: 21671382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Embryonic stem cell-derived glial precursors as a vehicle for sulfamidase production in the MPS-IIIA mouse brain.
    Robinson AJ; Zhao G; Rathjen J; Rathjen PD; Hutchinson RG; Eyre HJ; Hemsley KM; Hopwood JJ
    Cell Transplant; 2010; 19(8):985-98. PubMed ID: 20350350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus).
    Wang X; Ratnaraj N; Patsalos PN
    Seizure; 2004 Dec; 13(8):574-81. PubMed ID: 15519917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains.
    Hocquemiller M; Hemsley KM; Douglass ML; Tamang SJ; Neumann D; King BM; Beard H; Trim PJ; Winner LK; Lau AA; Snel MF; Gomila C; Ausseil J; Mei X; Giersch L; Plavsic M; Laufer R
    Mol Ther Methods Clin Dev; 2020 Jun; 17():174-187. PubMed ID: 31909089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA.
    Savas PS; Hemsley KM; Hopwood JJ
    Mol Genet Metab; 2004 Aug; 82(4):273-85. PubMed ID: 15308125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioinformatics classification of mutations in patients with Mucopolysaccharidosis IIIA.
    Tanwar H; Kumar DT; Doss CGP; Zayed H
    Metab Brain Dis; 2019 Dec; 34(6):1577-1594. PubMed ID: 31385193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration.
    Van De Vyver AJ; Walz AC; Heins MS; Abdolzade-Bavil A; Kraft TE; Waldhauer I; Otteneder MB
    Front Pharmacol; 2022; 13():958543. PubMed ID: 36105215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
    Gliddon BL; Hopwood JJ
    Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and characterization of wild type and mutant recombinant human sulfamidase. Implications for Sanfilippo (Mucopolysaccharidosis IIIA) syndrome.
    Perkins KJ; Byers S; Yogalingam G; Weber B; Hopwood JJ
    J Biol Chem; 1999 Dec; 274(52):37193-9. PubMed ID: 10601282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.
    Mariappan TT; Kurawattimath V; Gautam SS; Kulkarni CP; Kallem R; Taskar KS; Marathe PH; Mandlekar S
    Mol Pharm; 2014 Feb; 11(2):477-85. PubMed ID: 24380373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat.
    Yang Z; Brundage RC; Barbhaiya RH; Sawchuk RJ
    Pharm Res; 1997 Jul; 14(7):865-72. PubMed ID: 9244142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.